Systematic Review and Quality Appraisal of Literature on Economic Evaluation of Drugs for Type 2 Diabetes

Abstract

Objective To systematically evaluate the overall characteristics and quality of literature on economic evaluation of drugs for type 2 diabetes, and to provide recommendations for future research and related decision-making. Methods The economic evaluation literature on drugs for type 2 diabetes based on the Chinese population were searched from CNKI, Wanfang, VIP and PubMed databases. The literature that met the inclusion criteria was selected, and the key research elements were extracted. Meanwhile, the quality of health economics studies (QHES) was used to evaluate the quality of the literature. Results and Conclusion A total of 325 articles (296 in Chinese and 29 in English) were included. Most of the studies were conducted by medical institutions (247 articles, 76.0%) and they used cost-effectiveness analysis (295 articles, 90.8%). However, most of the included literature did not report study perspective (267 articles, 90.2%). The average QHES score of the included literature was 57.29, and the quality of the literature was concentrated in “low quality” (123 articles, 37.8%) and “average quality” (138 articles, 42.5%). Literature published in English journals, or using modeling methods, or from universities had relatively higher quality. The quality of economic evaluation literature on drugs for type 2 diabetes based on the Chinese population is generally low at present. There are many problems, such as single research institutions and methods, lack of research perspectives, and no sensitivity analysis.

Keywords

type 2 diabetes / economic evaluation / quality evaluating / QHES

References

[1] GBD 2016 disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390: 1211-1259.

[2] Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Research Clinical Practice, 2022, 183: 109119.

[3] Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)[J]. Chinese Journal of Diabetes Mellitus, 2021, 13 (4): 315-409.

[4] Liu Yahong, Chang Hongsheng, Zhu Yan, et al. Rational use of medication and progress in type 2 diabetes[J]. Sichuan Medical Journal, 2016, 37 (10): 1179-1183.

[5] American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45 (Supplement 1): S125.

[6] Sun Lihua. Pharmacoeconomics[M]. Beijing: China Medical Science Press, 2019.

[7] Walley T, Haycox A. Pharmacoeconomics: Basic concepts and terminology[J]. British Journal of Clinical Pharmacology, 1997, 43: 343-348.

[8] Tao Libo, Wang Fangxu. Closed-loop management mechanism of pharmacoeconomics in decision-making application[J]. China Journal of Pharmaceutical Economics, 2021, 16 (4): 31-33+44.

[9] Chen Chaoxin, Zheng Bin, Zheng Huanrui, et al. Evaluation of systematic evaluation of economics of generic drugs through the quality and efficacy consistency of generic drugs[J]. China Journal of Pharmaceutical Economics, 2020, 15 (7): 10-19.

[10] Chiou CF, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of costeffectiveness studies[J]. Med Care, 2003, 41 (1): 32-44.

[11] Zhang Di, Zou Yuanjun, Jin Taowei, et al. Quality of economic evaluation of opioid drugs for cancer pain treatment in China[J]. Chinese Journal of Gerontology, 2021, 41 (10): 2048-2052.

[12] Xu Ailin, Li Wenjun, Lu Mengqing. Quality appraisal of pediatric pharmacoeconomic research literatures in China from 2009 to 2018[J]. China Pharmacy, 2020, 31 (6): 718-723.

[13] Feng Yiman, Ke Xiatong, Tang Wenxi. Evaluation of the quality of Chinese literature in the pharmacoeconomic evaluation of antitumor drugs[J]. China Journal of Pharmaceutical Economics, 2021, 16 (4): 11-15.

[14] Lin Jie, Wang Shuo, Guo Dongmei. Literature of Chinese herbal medicine economics research from 2014 to 2018: A quality assessment[J]. Clinical Medication Journal, 2019, 17 (11): 49-52.

[15] Sun Mao, Feng Xiaoyuan, Gao Peng, et al. Quality evaluation of domestic pharmacoeconomics literatures in 2013[J]. China Pharmacy, 2015, 26 (17): 2308-2311.

[16] Yan Juntao, Bao Shiyi, Liu Liu, et al. Reporting quality of economic evaluations of the negotiated traditional Chinese medicines in national reimbursement drug list of China: A systematic review[J]. Integrative Medicine Research, 2023, 12 (1): 100915.